Phosphinate or Urea? Synthesis and Biological Evaluation of Prostate Specific Membrane Antigen‐Targeted Fluorophores With Different Zinc‐Binding Motif
Authors:
Open Access
- 26 May 2026
- journal article
- Published by Wiley in ChemMedChem
- Vol. 21 (10) , e70320
Abstract
Most prostate specific membrane antigen (PSMA)‐targeted drugs contain a urea‐based targeting vector, although high PSMA‐binding affinities have also been realized with other zinc‐binding motifs. This study describes the synthesis and evaluation of a hybrid compound containing a phosphinate motif (GPI) and a linker derived from an established urea‐based PSMA ligand (PSMA‐617). Fluorescent conjugates differing in their zinc‐binding motif only were synthesized and evaluated in vitro and in vivo. The phosphinate hybrid Cy5‐GPI617 ( 9 ) is more polar and has reduced binding affinity to human serum albumin (HSA) compared to its urea analog Cy5‐617 ( 10 ). At the same time, Cy5‐GPI617 ( 9 ) has an almost identical PSMA binding affinity (low nM) and leads to high, PSMA‐specific cellular uptake. In vivo, the phosphinate hybrid 9 showed reduced retention in nontumor tissues along with only moderately decreased tumor uptake compared to the urea analog 10 . These findings demonstrate that the previously performance‐limiting phosphate competition of GPI can be overcome by molecular engineering and highlight the potential of phosphinate‐based scaffolds for PSMA targeting.Keywords
This publication has 50 references indexed in Scilit:
- Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future DirectionsCurrent Oncology Reports, 2025
- A short review on the current status of PSMA ligands used for PSMA-PET/CT imagingmemo - Magazine of European Medical Oncology, 2025
- Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are goingCancer Treatment Reviews, 2024
- Prostate‐specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasmaThe Prostate, 2023
- Prostate-Specific Membrane Antigen–Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic OutcomesEuropean Urology, 2023
- GCP III is not the “off-target” for urea-based PSMA ligandsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Glycoforms of human prostate‐specific membrane antigen (PSMA) in human cells and prostate tissueThe Prostate, 2021
- Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPIIFEBS Open Bio, 2017
- An improved protocol for the preparation of (S)-vinylglycine from (S)-methionineAmino Acids, 2010
- Expression of Prostate‐Specific Membrane Antigen in Normal and Malignant Human TissuesWorld Journal of Surgery, 2006